EC approval for Delstrigo and Pifeltro HIV-1 treatments

29 November 2018

Following a positive recommendation from the European Medicines Agency’ advisory committee in September, the European Commission has now officially approved Delstrigo and Pifeltro for the treatment of HIV-1 infection, says US pharma giant Merck & Co’s (NYSE: MRK) local subsidiary, MSD.

Delstrigo is a new once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). It is indicated in the European Union for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiviral agents, lamivudine or tenofovir.

Pifeltro (doravirine, 100mg) is a new, once-daily NNRTI indicated in the EU in combination with other antiretroviral medicines for the treatment of adults with HIV-1 infection, without past or present evidence of resistance to the NNRTI class.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK